Pyxis Oncology, Inc.
PYXS
$1.70
$0.010.59%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -- | 49.10% | -3.77% | -6.09% | -549.82% |
| Total Depreciation and Amortization | -- | 426.73% | -27.91% | -8.55% | -50.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -91.40% | 82.43% | 65.08% | -16.55% |
| Change in Net Operating Assets | -- | 142.89% | 26.73% | -114.35% | 78.88% |
| Cash from Operations | -- | 45.95% | 9.46% | -474.09% | -8.81% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -39.00% | 143,600.00% | 382,500.00% | 186.64% |
| Cash from Investing | -- | -39.00% | 143,487.50% | 382,500.00% | 185.53% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -100.00% | -100.00% |
| Repurchase of Common Stock | -- | 99.07% | -700.00% | -55.81% | 98.98% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 1,238.00% | -100.48% | -160.91% | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -12.32% | 86.07% | 29.97% | -136.68% |